Madison, WI, United States of America

Steven Riddle

This inventor holds 2 USPTO granted patents. Top assignee: Life Technologies Corporation. Active years: 2013-2014.


% Patents Active = 50.0

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2013-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Steven Riddle

Introduction

Steven Riddle is an accomplished inventor based in Madison, WI (US). He has made significant contributions to the field of biosensors and molecular interactions. With a total of 2 patents, Riddle's work has advanced our understanding of kinase and ubiquination assays.

Latest Patents

Riddle's latest patents include innovative compositions that involve antibodies, polypeptides, and organic molecules. These inventions provide methods for probing molecular interactions, such as deubiquination, ubiquination, and kinase activity, utilizing resonance energy transfer (RET). Another notable patent focuses on biosensors, specifically modified ligand binding molecules. These biosensors, which can include phosphate binding proteins (PBPs), are designed to exhibit detectable changes in RET when binding or releasing ligands.

Career Highlights

Steven Riddle is currently employed at Life Technologies Corporation, where he continues to push the boundaries of scientific research. His work has been instrumental in developing new technologies that enhance our ability to study complex biological processes.

Collaborations

Riddle collaborates with notable colleagues, including Kurt William Vogel and Matthew B Robers. Their combined expertise fosters an environment of innovation and discovery.

Conclusion

Steven Riddle's contributions to the field of biosensors and molecular interactions exemplify the impact of innovative thinking in science. His patents reflect a commitment to advancing technology and improving our understanding of biological systems.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…